<DOC>
	<DOCNO>NCT01883323</DOCNO>
	<brief_summary>This phase II clinical study patient metastatic ( cancer spread part body ) melanoma . Patients receive infusion ( give vein ) autologous tumor infiltrate lymphocyte ( TILs ) . TILs type white blood cell recognize tumor cell enter cause tumor cell break . Prior cell infusion , patient receive two drug cyclophosphamide fludarabine prepare body receive TILs . After cell infusion , patient receive low-dose interleukin-2 therapy approve drug treat melanoma . This study see useful regimen treat metastatic melanoma .</brief_summary>
	<brief_title>Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Inclusion Criteria ( Eligibility TIL Evaluation ) : Must measurable , unresectable stage III stage IV melanoma Suitable tumor collection If tumor suitable collection , patient must suitable surgery Patient must 18 year age old Performance status ECOG 0 1 Life expectancy &gt; 5 month date consent TIL evaluation Willing test transmissible disease For patient history allergy penicillin , gentamycin , streptomycin , antifungal , ability generate TILs confirm cell manufacturing laboratory Inclusion Criteria ( Eligibility Treatment ) : Signed date informed consent No brain metastasis stable brain metastasis 3 month follow definitive treatment . Life expectancy &gt; 3 month date consent TILs treatment TILs suitable use determine laboratory More 30 day since prior systemic therapy time cell infusion , six week since prior nitrosurea therapy . For patient prior ipilimumab therapy , least six week must elapse last ipilimumab dose start study treatment . All side effect previous treatment must recover acceptable grade level . Adequate organ function Must positive EBV titre Women childbearing potential must negative pregnancy test . Patients gender must willing practice birth control treatment 6 month post completion IL2 treatment . Requiring systemic steroid therapy HIV positive With active hepatitis B hepatitis C , syphilis , HTLV Must active systemic infection , coagulation disorder active major medical illness cardiovascular , respiratory immune system , uncontrolled psychiatric disorder , condition may affect follow study procedure . Have active underlying cardiac illness define positive stress test , LVEF &lt; 40 % ongoing lifethreatening arrhythmias Abnormal lung function test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Measurable</keyword>
	<keyword>Unresectable</keyword>
	<keyword>Stage III</keyword>
	<keyword>Stage IV</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Tumor-Infiltrating Lymphocytes</keyword>
	<keyword>Low-Dose Interleukin-2</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Fludarabine</keyword>
</DOC>